e-Drug3D

1998

TIVOZANIB

INN
TIVOZANIB

cas 475108-18-0

CLASS

ANTINEOPLASTIC
TYROSINE KINASE INHIBITOR (VEGFR-1 VEGFR-2 VEGFR-3 AND PDGFR-BETA)

ROUTE (list)

ORAL

ATC code

L01EK03

PK parameters

Tmax 10 HOUR
VD 123 LITER
Cl 0.75 LITER / HOUR
PPB 99 PERCENT
t1/2 111 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER (0.09 MILLIGRAM PER MILLILITER)

Target

TARGET VEGFR-1 VEGFR-2 VEGFR-3 PDGFR-BETA

PDB
4ASE (CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951))

Download experimental 3D coordinates of AV9 with added hydrogens

Vascular endothelial growth factor receptor 1 UNIPROT P17948 FLT1

Vascular endothelial growth factor receptor 2 UNIPROT P35968 KDR

Download SDF file

Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-

Formula:
C22H19ClN4O5

Calculated chemical properties:

MW 454.86
NB_atoms 32
XLogP 5.64
PSA 102.168
NB_HD 2
NB_HA 9
fsp3 0.14
Lipinski(0=no;1=yes) 0

FDA
NDA 212904 (label) INN (TIVOZANIB HYDROCHLORIDE) FOTIVDA (AVEO PHARMS) APPROVAL= AP YEAR= 2021 NEWMOLECULARENTITY